E-LIB Suche - Ergebnisse für: Pratley, R.E.

1

IDF2022-0796 Sustained weight loss with ertugliflozin in pa..:

Cosentino, F. ; Dagogo-Jack, S. ; Frederich, R....
Diabetes Research and Clinical Practice. 197 (2023) - p. 110329 , 2023

Link: https://doi.org/10.1016/..

2

Prevalence of systemic inflammation in individuals with ath..:

Marx, N ; Deanfield, J E ; Gerward, S...
European Heart Journal. 44 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

3

WCN23-0356 HYPOGLYCEMIA AND KIDNEY EVENTS IN PARTICIPANTS W..:

Cherney, D. ; Cosentino, F. ; E. Pratley, R....
Kidney International Reports. 8 (2023) 3 - p. S191-S192 , 2023

Link: https://doi.org/10.1016/..

4

Efficacy of ertugliflozin on hospitalisation for heart fail..:

Pandey, A ; Kolkailah, A A ; Cosentino, F...
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

5

Mediators of the effect of ertugliflozin on a composite kid..:

Cherney, D Z I ; Segar, M ; Pandey, A...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

6

Cardiorenal outcomes with ertugliflozin by baseline metform..:

Cosentino, F ; Cannon, C P ; Cherney, D Z I...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

7

POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF..:

Cherney, D. ; Charbonnel, B. ; Cosentino, F....
Kidney International Reports. 6 (2021) 4 - p. S154-S155 , 2021

Link: https://doi.org/10.1016/..

8

Mediation analyses of the effect of ertugliflozin on hospit..:

Segar, M W ; Pandey, A ; Cherney, D Z I...
European Heart Journal. 42 (2021) Supplement_1 - p. , 2021

Link: https://doi.org/10.1093/..

9

Characteristics of adult‐ compared to childhood‐onset type ..:

Casu, A. ; Kanapka, L. G. ; Foster, N. C....
Diabetic Medicine. 37 (2020) 12 - p. 2109-2115 , 2020

Link: https://doi.org/10.1111/..

10

Efficacy and safety of initial combination therapy with alo..:

Pratley, R. E. ; Fleck, P. ; Wilson, C.
Diabetes, Obesity and Metabolism. 16 (2014) 7 - p. 613-621 , 2014

Link: https://doi.org/10.1111/..

11

Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin..:

DeFronzo, R. A. ; Burant, C. F. ; Fleck, P....
The Journal of Clinical Endocrinology & Metabolism. 97 (2012) 5 - p. 1615-1622 , 2012

Link: https://doi.org/10.1210/..

12

Efficacy and tolerability of taspoglutide versus pioglitazo..:

Pratley, R. E. ; Urosevic, D. ; Boldrin, M...
Diabetes, Obesity and Metabolism. 15 (2012) 3 - p. 234-240 , 2012

Link: https://doi.org/10.1111/..

13

Comparison of vildagliptin and thiazolidinedione as add‐on ..:

Blonde, L. ; Dagogo‐Jack, S. ; Banerji, M. A....
Diabetes, Obesity and Metabolism. 11 (2009) 10 - p. 978-986 , 2009

Link: https://doi.org/10.1111/..

14

Combination alogliptin plus pioglitazone treatment in patie..:

DeFronzo, R. ; Burant, C.F. ; Fleck, P....
Canadian Journal of Diabetes. 33 (2009) 3 - p. 257-258 , 2009

Link: https://doi.org/10.1016/..

15

Robust improvements in fasting and prandial measures of β‐c..:

Pratley, R. E. ; Schweizer, A. ; Rosenstock, J....
Diabetes, Obesity and Metabolism. 10 (2008) 10 - p. 931-938 , 2008

Link: https://doi.org/10.1111/..